title: The chemotherapy of metastatic gastric adenocarcinomas with hypersecretion of alpha-fetoprotein or beta-human chorionic gonadotrophin: report of two cases.
abstract: The chemotherapy of advanced gastric adenocarcinomas (GAs) is based on agents such as cisplatin, 5-fluorouracil and anthracyclins. Reproducible objective response rates are reported as approximately 40%. However, the median survival remains short, not exceeding 10 months. Amongst GA, a subset of tumours with increased plasma alpha-fetoprotein (alphaFP) and/or beta human chorionic gonadotrophin (betaHCG) levels form a well-defined histopathological entity. This subgroup has been associated with poor prognosis, due to the presence of poorly differentiated and rapidly proliferating cells. No specific chemotherapy has been proposed for this particular form of GA. We report two cases of patients with GA and hypersecretion of alphaFP and/or betaHCG. Despite bulky liver metastases and resistance to two standard chemotherapy regimens, both patients exhibited sensitivity to chemotherapy combining bleomycin, oxaliplatin and etoposide. These results suggest that patients with this particular subset of GA may benefit from chemotherapy regimens similar to those given to germ-cell tumour patients.
authors.affiliation: Service de Cancérologie, Hĵpital Paul Brousse, Villejuif, France.
authors.forename: N
authors.initials: N
authors.lastname: Germann
authors.forename: M
authors.initials: M
authors.lastname: Gross-Goupil
authors.forename: E
authors.initials: E
authors.lastname: Wasserman
authors.forename: J F
authors.initials: JF
authors.lastname: Emile
authors.forename: J L
authors.initials: JL
authors.lastname: Misset
authors.forename: M
authors.initials: M
authors.lastname: Reynes
authors.forename: F
authors.initials: F
authors.lastname: Goldwasser
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016019:Survival Analysis; D000509:alpha-Fetoproteins / Q000378:metabolism*
chemical_list: D018997:Chorionic Gonadotropin, beta Subunit, Human; D009944:Organoplatinum Compounds; D000509:alpha-Fetoproteins; D000077150:Oxaliplatin; D001761:Bleomycin; D005047:Etoposide